Key result
Combined-release isosorbide-5-mononitrate reduces ischemic episodes and improves exercise capacity without inducing tolerance.
Why the study?
Does a combined immediate-release and sustained-release preparation of isosorbide-5-mononitrate improve symptoms in patients with angina pectoris?
Does a combined immediate-release and sustained-release preparation of isosorbide-5-mononitrate improve symptoms in patients with angina pectoris?
Answers are grounded in this paper and cite their sources.
A once-daily combined immediate and sustained-release formulation of isosorbide-5-mononitrate provides rapid antianginal efficacy without inducing tolerance.
The clinical efficacy of a combined immediate-release and sustained-release preparation of isosorbide-5-mononitrate for angina pectoris is observed within a few minutes of administration. The preparation reduces the number of silent and painful ischaemic episodes and increases work and exercise capacity. The pharmacokinetic profiles accord with the circadian variation in cardiovascular disease. Drug levels fall significantly at night and tolerance to the haemodynamic and antianginal effects is not seen. Once-daily administration is appreciated by patients. The preparation also shows promise in treating heart failure.
No takes yet. Share an insight, caveat, or question.
Arthur et al. (1999) conducted a review in angina pectoris. combined immediate-release and sustained-release preparation of isosorbide-5-mononitrate was evaluated. A combined immediate-release and sustained-release preparation of isosorbide-5-mononitrate reduced silent and painful ischaemic episodes and increased exercise capacity without inducing tolerance.
Synapse has enriched 10 related papers. Consider them for comparative context: